Revenue: As of FY2026 Q1, the actual value is USD 485 K.EPS: As of FY2026 Q1, the actual value is USD -0.13.EBIT: As of FY2026 Q1, the actual value is USD -2.017 M.Firefly Neuroscience, Inc. operates as one reportable segment, “Firefly Products” .<h4>Revenue</h4>Revenue for the three months ended March 31, 2026, was $485 thousand, a 1028% increase from $43 thousand for the same period in 2025, primarily driven by revenue from the acquisition of Evoke Neuroscience .<h4>Gross Profit</h4>Gross profit for the three months ended March 31, 2026, was $221 thousand, up from $43 thousand in the prior year .<h4>Operating Expenses</h4><ul><li>Cost of Goods Sold: Cost of goods sold increased to $264 thousand for the three months ended March 31, 2026, from $0 in the corresponding period of 2025, mainly due to Evoke material costs (38%) and people costs (47%) .</li><li>Research and Development Expenses: These expenses rose by 36% to $424 thousand in Q1 2026 from $312 thousand in Q1 2025, primarily due to increased spending on product development .</li><li>Selling and Marketing Expenses: These expenses decreased by 32% to $141 thousand in Q1 2026 from $208 thousand in Q1 2025, mainly due to headcount reductions (41%) and a decrease in outside consultants (42%) .</li><li>General and Administration Expenses: General and administration expenses increased by 5% to $1,666 thousand in Q1 2026 from $1,588 thousand in Q1 2025, attributed to regular business operating expenses .</li><li>Total Operating Expenses: Total operating expenses increased to $2,231 thousand in Q1 2026 from $2,108 thousand in Q1 2025 .</li></ul><h4>Operating Loss</h4>The operating loss decreased to -$2,010 thousand for the three months ended March 31, 2026, compared to -$2,065 thousand for the same period in 2025 .<h4>Other Income (Expense)</h4>Other income (expense) was $6 thousand for Q1 2026, a significant improvement from -$10,865 thousand in Q1 2025, largely due to the settlement of a Convertible Promissory Note in Q1 2025, which had resulted in a $10,722 thousand expense .<h4>Net Loss</h4>Net loss for the three months ended March 31, 2026, was -$2,004 thousand, a decrease in loss compared to -$12,930 thousand in the prior year period .<h4>Cash Flow</h4><ul><li>Operating Activities: Net cash used in operating activities decreased to -$1,948 thousand for the three months ended March 31, 2026, from -$2,511 thousand in Q1 2025, primarily due to a reduction in debt in Q1 2025 .</li><li>Investing Activities: Net cash used in investing activities increased to -$58 thousand in Q1 2026 from -$7 thousand in Q1 2025, mainly due to the acquisition of equipment for building additional Evoke Systems .</li><li>Financing Activities: Net cash provided by financing activities decreased to $2,386 thousand in Q1 2026 from $10,253 thousand in Q1 2025, primarily due to warrant exercises in Q1 2025 .</li></ul><h4>Liquidity and Capital Resources &amp; Outlook</h4>As of March 31, 2026, Firefly Neuroscience, Inc. had cash of $3,127 thousand, an increase from $2,747 thousand as of December 31, 2025 . This increase reflects net proceeds from the initial closing of a private placement, partially offset by cash used in operating and investing activities . Subsequent to March 31, 2026, the company raised an additional $8,000 thousand in gross proceeds through an additional closing of the same private placement and entered into a new securities purchase agreement for up to $1,000 thousand in additional gross proceeds . Firefly Neuroscience, Inc. anticipates continued negative cash flows from operations for the next 12 months as it integrates products and expands its sales organization, and expects to require substantial additional capital to fund ongoing operations and implement its business strategy until it achieves profitability . There is substantial doubt about the company’s ability to continue as a going concern, but management plans to address this through disciplined operating expense management, targeted commercial expansion, and continued access to capital markets .

Firefly Neuroscience | 10-Q: FY2026 Q1 Revenue: USD 485 K